Antisense oligonucleotides targeting FANCM show preclinical promise in ALT-positive cancers
Feb. 28, 2025
A recent study by researchers from Nanyang Technological University identified Fanconi anemia complementation group M (FANCM) as a crucial regulator of alternative lengthening of telomere (ALT), aiming to develop new antisense oligonucleotides (ASOs) to suppress its function.